Absci (ABSI) Short term Debt (2020 - 2025)

Absci (ABSI) posted Short term Debt of $12.8 million for Q3 2025, little changed sequentially from $12.8 million in Q2 2025.

Absci (ABSI) Short term Debt (2020 - 2025) Analysis & Trends

Absci has reported Short term Debt for 4 years, with the latest figure at $12.8 million in Q3 2025.

Quarterly Short term Debt changed N/A year-over-year to $12.8 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $12.8 million (changed N/A YoY) and the FY2024 annual result came in at $12.8 million, changed 0.0% from the prior year.
Short term Debt held at $12.8 million in Q3 2025 per ABSI's latest filing, from $12.8 million in the prior quarter.
Over five years, Short term Debt peaked at $12.8 million in Q4 2023 and troughed at $12.8 million in Q4 2023.
A 3-year average of $12.8 million and a median of $12.8 million in 2023 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 0.0% in 2024, down 0.0% in 2024.
Over 3 years, Short term Debt stood at $12.8 million in 2023, then changed by 0.0% to $12.8 million in 2024, then changed by 0.0% to $12.8 million in 2025.
According to Business Quant data, Short term Debt over the past three periods registered $12.8 million, $12.8 million, and $12.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Absci	1.58 Bn	1.37 Bn	-

Download Data